NCT01792206

Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease

EFFECT OF PARICALCITOL (ZEMPLAR) ON ENDOTHELIAL FUNCTION AND INFLAMMATION IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Scott and White Hospital & Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to study the effects of paricalcitol on endothelial function and inflammation, cardiovascular risk factors which are associated with patient populations that have Type 2 diabetes and Stage 3 and 4 Chronic Kidney Disease (CKD). Hypothesis 1: The state of CKD is associated with oxidative stress and inflammation and impaired post ischemic endothelium dependent flow mediated vasodilation which may contribute to atherogenesis. Hypothesis 2: The administration of paracalcitol to patients with CKD will suppress oxidative stress and inflammation and improve endothelial function and thus contribute to an anti-atherogenic action.

Conditions

• Type 2 Diabetes
• Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	Zemplar	Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
DRUG	Placebo	Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months

Timeline

• Start date: 2009-09-01
• Primary completion: 2012-11-01
• Completion: 2013-02-01
• First posted: 2013-02-15
• Last updated: 2013-02-15

Locations

4 sites across 1 country: United States